Biogen (NASDAQ:BIIB) executives outlined their rationale and financial expectations for a proposed acquisition of Apellis during a business update call, positioning the deal as a way to add near-term commercial growth while deepening the company’s push into immunology, rare disease, and nephrology.
Strategic rationale: adding post-Phase III growth assets
President and CEO Chris Viehbacher said Biogen has been clear about how it evaluates mergers and acquisitions, emphasizing it is not seeking to take “a lot of phase III risk” given its existing late-stage pipeline. Viehbacher noted Biogen’s pipeline is viewed internally as “high-conviction,” but he expects that pipeline “doesn’t really start to contribute to growth until 2028,” with launches taking time to reach peak sales.
Commercial assets: Syfovre and Empaveli
Adam Keeney, Head of Corporate Development, said the acquisition would add “two best-in-class products” to Biogen’s growth portfolio: Syfovre in geographic atrophy (GA) and Empaveli across rare hematology and kidney diseases.
Keeney described Syfovre as “the first FDA-approved therapy for Geographic Atrophy,” calling GA a “serious immune-mediated retinopathy” that can lead to irreversible vision loss. He said the U.S. market is “large” and “underpenetrated,” citing an estimate of 1.5 million patients diagnosed in the U.S. with “very few currently being treated.” Keeney said Biogen is taking “a realistic view” on future growth given competition, but argued Syfovre’s profile, plus Biogen’s U.S. capabilities and Apellis’ sales and marketing team, could help the product “realize its full potential.” He also highlighted a planned prefilled syringe as a potential support for differentiation.
On Empaveli, Keeney said the drug has been approved in PNH and is commercialized by Sobi outside the U.S., and more recently gained approval in C3G and IC-MPGN. He characterized these as rare immune-mediated kidney diseases with substantial burden, stating that “50% of patients reach end-stage kidney disease within 10 years.” He added that Empaveli is “the only FDA-approved therapy” for both adults and pediatric patients in primary IC-MPGN as well as pediatric C3G and post-transplant C3G recurrence, and said registrational studies showed benefits across proteinuria, kidney function stabilization, and clearance of C3 deposits.
Nephrology build-out and felzartamab synergy
Viehbacher called nephrology a “new area” for Biogen and said the Apellis acquisition would accelerate capability-building ahead of Biogen’s own kidney program, felzartamab. He pointed to overlap in physician targets, saying there is “about a 50% overlap” between physicians prescribing Empaveli and those expected to prescribe in IgAN, and also overlap with physicians who will prescribe for AMR. Viehbacher argued that if felzartamab trials succeed, the company could have “a running start into the launch” and potentially reach peak sales faster than building a nephrology footprint alone.
During Q&A, Alisha Alaimo, President and Head of North America, said Empaveli is in “early days” of launch and that patient start form demand has been “quite encouraging.” She said early indicators show prescribing across multiple patient types, including pediatric, adult, native kidney, and post-transplant patients. Alaimo added that adoption in C3G may occur more quickly than in IC-MPGN due to challenges diagnosing and recognizing primary IC-MPGN. She described the early launch trajectory as “nice linear growth,” rather than a one-time bolus typical of some rare disease launches.
Priya Singhal, Head of Development, said Biogen is evaluating Apellis’ complement-related pipeline and early-stage programs, including “the siRNA,” and is assessing potential next indications, though she emphasized the evaluation is still early.
Financial terms, financing, and expected accretion
Robin Kramer, Chief Financial Officer, said Biogen plans to acquire Apellis for $41 per share, representing approximately $5.6 billion in upfront cash consideration, plus contingent value rights tied to achieving thresholds related to global sales of Syfovre. Kramer said Biogen expects to finance the acquisition through a combination of cash on hand, revolver borrowings, and a bank term loan.
Kramer estimated the impact of financing costs and foregone interest income at $120 million-$130 million in both 2026 and 2027, and said Biogen expects to repay the transaction-related borrowings by the end of 2027. She said the deal is subject to customary closing conditions and is expected to close in the second quarter of 2026.
On performance expectations, Kramer said Biogen expects combined revenue from Syfovre and Empaveli to grow in the “mid- to high teens for at least the next two years,” adding that near-term estimates are consistent with analyst consensus. She said the transaction is expected to become “increasingly accretive starting in 2027,” and that Biogen believes it will “meaningfully” increase its non-GAAP diluted EPS CAGR through the end of the decade. Kramer said Biogen plans to update full-year 2026 guidance when it reports first-quarter earnings.
Viehbacher said Biogen began evaluating Apellis “well over a year ago,” initially concluding that market forecasts and company projections “were probably running ahead” of what its research suggested, and only engaged later when forecasts were more aligned. He also said the Apellis commercial team is about 350 people, though Biogen has not conducted a detailed role-by-role review.
On the CVR, Keeney said the sales tiers were “more aspirational,” and that Biogen’s base case model does not assume they will be achieved. He added that if the thresholds are reached, it would signal “very significant additional value” generated, with some shared with Apellis shareholders.
About Biogen (NASDAQ:BIIB)
Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.
The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.
